Abstract | OBJECTIVE: We evaluated recent use trends and predictors of first-line antidiabetes treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Using two large U.S. health insurance databases (Clinformatics and Medicare), we identified adult patients with type 2 diabetes who initiated antidiabetes treatment from 2013 through 2019. Quarterly trends in use of first-line antidiabetes treatment were plotted overall and stratified by cardiovascular disease (CVD). Multinomial logistic regressions were fit to estimate predictors of first-line antidiabetes treatment, using metformin, the recommended first-line treatment for type 2 diabetes, as the common referent. RESULTS:
Metformin was the most frequently initiated medication, used by 80.6% of Medicare beneficiaries and 83.1% of commercially insured patients. Sulfonylureas were used by 8.7% (Medicare) and 4.7% (commercial). Both populations had low use of sodium-glucose cotransporter 2 inhibitors (SGLT-2i, 0.8% [Medicare] and 1.7% [commercial]) and glucagon-like peptide 1 receptor agonists (GLP-1Ra; 1.0% [Medicare] and 3.5% [commercial]), with increasing trends over time (P < 0.01). Initiators of antidiabetes drugs with established cardiovascular benefits (SGLT-2i and GLP-1RA) were more likely to be younger and had prevalent CVD or higher socioeconomic status compared with initiators of metformin. CONCLUSIONS: Among adult patients with type 2 diabetes, metformin was by far the most frequent first-line treatment. While the use of SGLT-2i and GLP-1RA was low from 2013 through 2019, it increased among patients with CVD.
|
Authors | HoJin Shin, Sebastian Schneeweiss, Robert J Glynn, Elisabetta Patorno |
Journal | Diabetes care
(Diabetes Care)
Vol. 44
Issue 8
Pg. 1774-1782
(08 2021)
ISSN: 1935-5548 [Electronic] United States |
PMID | 34385345
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 by the American Diabetes Association. |
Chemical References |
- Glucagon-Like Peptide-1 Receptor
- Hypoglycemic Agents
- Pharmaceutical Preparations
- Sodium-Glucose Transporter 2 Inhibitors
- Glucose
|
Topics |
- Adult
- Aged
- Diabetes Mellitus, Type 2
(drug therapy, epidemiology)
- Glucagon-Like Peptide-1 Receptor
- Glucose
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Medicare
- Pharmaceutical Preparations
- Sodium-Glucose Transporter 2 Inhibitors
- United States
(epidemiology)
|